Navigation Links
FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
Date:11/4/2010

INDIANAPOLIS, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis. This is the fifth indication the FDA has approved for Cymbalta.

Cymbalta, which has been shown to significantly reduce chronic low back pain and chronic pain due to osteoarthritis, is a non-narcotic pain reliever that is meant to be taken once a day, every day by people with these pain conditions.

"People with chronic musculoskeletal pain often struggle to find a medication that works for them. The approval of Cymbalta for chronic musculoskeletal pain by the FDA gives doctors another option to help an underserved and suffering group of patients," said Michael Clark, M.D., MPH, director, Chronic Pain Treatment Program, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins Medical Institutions.

Although the exact way that Cymbalta works to reduce chronic musculoskeletal pain is unknown, it is believed that Cymbalta helps lessen pain by enhancing the body's natural pain suppressing system by increasing the activity of serotonin and norepinephrine in the brain and spinal cord.

In chronic musculoskeletal pain clinical studies, the most commonly observed adverse events (those occurring in at least 5 percent of study participants taking Cymbalta and at least twice the rate of placebo) in Cymbalta-treated patients with chronic low back pain were nausea, dry mouth, insomnia, sleepiness, constipation, dizziness and fatigue. The most commonly observed adverse events in Cymbalta-treated patients with chronic pain due to osteoarthritis were nausea, fatigue and constipation.

"It's important that p
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves New Indication for Afinitor
2. FDA Approves Teflaro for Bacterial Infections
3. FDA Approves Latuda to Treat Schizophrenia in Adults
4. FDA Approves Additional Medical Indication for Sprycel
5. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
6. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
7. FDA Approves Botox to Treat Chronic Migraine
8. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
9. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
10. FDA Approves Combination Contraceptive Containing a Folate
11. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/29/2015)... Denmark , July 29, 2015  Ascendis Pharma ... company that applies its innovative TransCon technology to address ... host a conference call on July 30, 2015, at ... from a Phase 2 pediatric study of once-weekly TransCon ... of the top-line results before the market opens on ...
(Date:7/29/2015)... , July 29, 2015 Unilife ... a developer, manufacturer and supplier of injectable drug ... Imperium™ platform of instant patch pumps for insulin. ... multi-day wearable insulin pump that does not require ... is prefilled and pre-assembled like an insulin pen, ...
Breaking Medicine Technology:Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2Unilife Introduces World's First Instant Patch Pump for Insulin 2Unilife Introduces World's First Instant Patch Pump for Insulin 3Unilife Introduces World's First Instant Patch Pump for Insulin 4
...  Provenance Biopharmaceuticals Corp. ("Provenance") announced today the closing ... Enterprises, LLC for the continued development of anti-cancer ... class of molecules called immunocytokines that are being ... cancer.  Immunocytokines, combine the immune stimulating features of ...
... 22, 2011   Marken announced today that Steve Roese ... organization, which will support Marken,s continued investment in their ... world.  Marken is now accelerating construction of several new depot ... existing locations in Singapore , Mexico and ...
Cached Medicine Technology:Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement 2Marken Appoints New Head of Global Quality Assurance 2
(Date:7/30/2015)... ... , ... New research finds some distinct differences in the way mesothelioma behaves ... Surviving Mesothelioma website. , Researchers with the National Institutes of Health, the FDA, ... mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) occurred in ...
(Date:7/30/2015)... ... July 30, 2015 , ... Political unrest is ... according to a new survey by leading international insurance provider Clements Worldwide. The ... medical expenses represented the largest sources of financial losses among respondents. , Twenty-eight ...
(Date:7/30/2015)... ... July 30, 2015 , ... HEALTHCAREfirst , the leading provider of ... that it is hosting a free webinar detailing the 2016 proposed rule from CMS ... and former Vice President of Regulatory Affairs for the National Association for Home Care ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... manufacturing and packaging services for consumer brands, recently completed a consolidation of all ... MD. Previously, the company operated out of two separate locations situated 11 miles ...
(Date:7/29/2015)... ... 2015 , ... Macro Wealth Management (MWM) Presidents have increased the ... program by encouraging their clients to donate their MWM planning fees to the Foundation. ... and Tim Streid, who see charitable giving as an important part of financial planning ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2
... Entire Health Care System More EffectiveWASHINGTON, Jan. 5 ... avoid hospitalization by using special technology provided by the ... to a recent study. "The study showed that ... improves patients, access to care and is easy to ...
... Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... definitive, 3-year distribution agreement with Alliance Lithomobile, a Division ... This agreement supersedes the interim agreement announced on November ...
... Only 17 percent of Spanish-speaking women of childbearing age ... folic acid daily, according to the first- nationally representative ... , Folic acid can prevent neural tube defects ... such as spina bifida and anencephaly, which are more ...
... Jan. 5 Cambrex Corporation (NYSE: ... M. Klosk, President and Chief Executive Officer, will ... January 13, 2009 at 9:00 a.m. PST at ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )A live ...
... new study reveals that the metadherin gene (MTDH) plays ... chemotherapy. The research, published by Cell Press in the ... , identifies MTDH as a promising therapeutic target for ... resist currently available therapeutic regimens and succumb to recurrent ...
... to help healthcare providers put a cap on ... Corporation ( MSC ) will introduce a new ... all healthcare team members who care for hospital ... on medical simulation , the International Meeting ...
Cached Medicine News:Health News:VA Data Show Home Health Technology Improves Access to Care 2Health News:Misonix Announces New HIFU Distribution Agreement for Italy 2Health News:Misonix Announces New HIFU Distribution Agreement for Italy 3Health News:Folic acid survey of Spanish-speaking women finds most are missing benefits, March of Dimes says 2Health News:Gene plays dual role in breast cancers with poor prognosis 2Health News:Medical Simulation Corporation to Introduce Ventilator Associated Pneumonia Program at International Meeting on Simulation in Healthcare 2Health News:Medical Simulation Corporation to Introduce Ventilator Associated Pneumonia Program at International Meeting on Simulation in Healthcare 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: